Research Material at the US and Canadian Border: Regulatory Status and What the Paperwork Has to Say

A shipment's regulatory status at the border is not settled by the phrase printed on the label. It is settled by two authorities applying two different tests, and a parcel has to satisfy both. Customs — U.S. Customs and Border Protection, or the Canada Border Services Agency — decides classification, valuation and entry: what the article is, what it is worth, and whether the declaration describing it is accurate. The health regulator — the FDA in the United States, Health Canada in Canada — decides admissibility: whether an article of that description may lawfully cross at all. A research-use-only designation speaks to the second question without answering it, because under both systems the regulatory character of an article is inferred from the whole record of how it is offered and described, not from one line of text ^[6][1].

What follows is the documentary shape of that for a US or Canadian recipient. It is reference material, not legal advice, and facts still in motion are flagged where they appear.

Two agencies, two tests: who decides whether a parcel enters

In the United States, CBP administers entry while the FDA holds the admissibility decision for articles within its jurisdiction; imports are presented to CBP, and where the FDA takes an interest the goods are held pending its determination ^[5]. In Canada the arrangement is formalised: CBSA assists Health Canada with the administration of the Food and Drugs Act at the border, and Health Canada determines admissibility. CBSA's memorandum is blunt about liability — importers are responsible for ensuring imported commodities comply with the applicable legislation, and may be held responsible for all costs of moving, destroying, disposing of or exporting goods Health Canada has deemed inadmissible ^[3].

Two practical consequences follow. Canadian declarations for regulated health commodities move through the Single Window Integrated Import Declaration, which carries Health Canada data elements alongside the customs data; missing or wrong elements can attract an Administrative Monetary Penalty regardless of what the health regulator decides ^[3]. And commercial importation of human drugs into Canada, including active ingredients, generally requires a Drug Establishment Licence or Site Licence — a question about the importer, settled before any parcel is packed ^[3].

What "research use only" does, and what it cannot do

The US doctrine is codified. Under 21 CFR 201.128, "intended uses" refers to the objective intent of the persons legally responsible for the labelling of an article, and that intent may be shown by labelling claims, advertising matter, or oral or written statements — the label is one input among several, not the controlling one ^[6]. Health Canada's position is stated more directly still. In an April 2026 public advisory on unauthorized injectable peptides sold online, the department addressed the wording itself.

This type of labelling does not make these products legal or exempt from regulatory requirements.

Health Canada, public advisory on unauthorized injectable peptides, April 2026

That sentence is narrower than either side of the argument usually claims. It does not say research material is contraband. It says the phrase carries no exempting force — a designation cannot, by itself, move an article outside a definition it otherwise falls inside. The same advisory records that Health Canada has seized unauthorized injectable peptide products and is working with CBSA to stop unauthorized shipments entering the country ^[1].

The 2026 Canadian enforcement line, and what it actually changed

On 11 June 2026 the Superior Court of Québec granted Health Canada a permanent injunction against an online retailer, Canlab Research, and its representatives, barring them from manufacturing, testing, distributing or selling unauthorized injectable peptides in Canada, or assisting others in doing so; the department announced the order publicly in late July ^[2]. It followed a run of seizures across 2025 and repeated earlier enforcement steps against the same seller ^[1][2].

Be precise about what that means. An injunction binds named parties. It is not a regulation, it did not amend the Food and Drugs Act, and it created no prohibition the statute did not already contain. What it changed is the evidentiary picture: a court-endorsed application of the existing definitions to online peptide sales, alongside a public advisory and an active border-cooperation arrangement ^[1][3]. The Canadian enforcement posture in this category is documented and current, and the description on the paperwork will be read against it.

The April 2026 compounding-list change, and what it does not do

The most misreported US development of 2026 concerns pharmacy compounding, not imports. The FDA sorts bulk drug substances nominated for use by compounding pharmacies under section 503A into categories; Category 2 holds substances that may present significant safety risks ^[18]. In April 2026 the FDA removed twelve peptides, including BPC-157 and TB-500, from Category 2 after their nominations were withdrawn, effective 22 April, without adding them to Category 1 ^[18][20]. Seven of the twelve then went before the Pharmacy Compounding Advisory Committee on 23–24 July 2026, which considered whether to recommend them for the 503A bulks list ^[19].

Leaving Category 2 authorised nobody to sell or import anything: the categories govern what a licensed pharmacy may compound, and none of the twelve became an approved drug. What it changes for a research buyer: nothing about legality, and for detention risk only this — the FDA's safety concerns about each substance now sit in a public advisory-committee record, while the test applied at the border, approval status read against intended use, is unchanged ^[5][6][19].

The commercial invoice: what the regulation actually requires

Most import problems that look regulatory are documentation problems. The US invoice requirements are a closed list at 19 CFR 141.86, and more demanding than the one-line description most reagent invoices carry: among other things, a detailed description including the name by which each item is known and its grade or quality, the quantities, the purchase price and currency of the sale, the country of origin, adequate detail of what each individual package contains, and English text or an accurate English translation ^[7].

The recurring failure is the description field. "Peptide", "chemical sample", "lab supplies" and "gift" are all inadequate under the regulation as written, and they generate holds because a description that could mean anything invites an officer to find out which thing it means ^[7]. Naming the substance, its form, its grade and the quantity present is both compliant and, in practice, faster.

HS classification, and why "choose the quieter code" is bad advice

Classification under the Harmonized System is a legal determination, not a preference, governed by the General Rules of Interpretation: the terms of the headings and the relevant section and chapter notes, applied to the goods as presented ^[13]. Several headings can genuinely be in play for peptide material, depending on what the article is and where a peptide stops counting as a peptide: Chapter 29 covers separate chemically defined organic compounds, with heading 2937 for hormones and their derivatives used primarily as hormones; heading 3504 covers peptones and other protein substances not elsewhere specified; and heading 3822 covers prepared diagnostic or laboratory reagents and certified reference materials ^[13].

Vendor pages circulate a specific piece of advice: that declaring under the reagent heading draws less scrutiny than declaring under the hormone heading. Selecting a code to change the level of inspection rather than to describe the goods is a material false statement in the entry. 19 U.S.C. § 1592 prohibits entering merchandise by means of a material and false document, statement or omission, whether or not the government loses revenue, and grades civil penalties across fraud, gross negligence and negligence, with fraud exposed up to the domestic value of the merchandise ^[8]. Canada reaches the same conduct through its penalty system for inaccurate declarations ^[3].

De minimis: suspended in the US, narrow in Canada

This is the fastest-moving fact here. Duty-free de minimis entry into the United States — the allowance for shipments valued at $800 or under — was suspended for all countries for goods entered for consumption on or after 29 August 2025, with separate treatment for goods moving through the international postal network ^[10]. The suspension rested on emergency economic powers; in February 2026 the Supreme Court held that the same statute does not authorise tariffs, without itself resolving the legality of the de minimis suspension, which continued in the lower courts ^[11]. Check current CBP guidance rather than any article, this one included.

Canada's arrangement is stable but narrow. Under CUSMA, courier shipments from the United States or Mexico are duty- and tax-free up to CAD 40, and duty-free but taxable above CAD 40 up to CAD 150; the low-value shipment threshold for streamlined accounting is CAD 3,300. Those commitments cover only goods shipped by courier from the US or Mexico ^[12]. None of these thresholds touch admissibility: value and legality are separate questions decided by different agencies.

If the parcel is held: the clocks and powers that actually apply

US procedure has real deadlines. Customs must notify the importer no later than five days, excluding weekends and holidays, after a decision to detain; merchandise not released within 30 days of presentation is deemed excluded by operation of law, which is when an administrative protest becomes available ^[9]. Where the FDA decides, the owner or consignee receives notice and may appear and introduce testimony before a refusal of admission is finalised ^[5]. Since 2012 the FDA may also destroy a refused drug valued at $2,500 or less without offering the option to export it, after notice and an opportunity to present testimony ^[5]. For small consignments there is often no re-export to fall back on.

Import alerts make holds systematic rather than random. Import Alert 66-41 provides for detention without physical examination of unapproved new drugs promoted in the United States, listing named firms and products; a shipment caught by it is detained on paper, and the burden sits with the owner or consignee to present evidence that it does not contain unapproved new drug products ^[4]. The alert is revised regularly; the current revision is dated May 2026 ^[4].

Import Alert 66-78 works on laboratory results rather than promotion. The FDA samples drugs and active ingredients it considers at risk of contamination, substandard quality or ingredient substitution; where analysis reveals a potential health risk, later shipments from the listed firm can be detained without physical examination, and removal requires the firm to show the problem is resolved, which may take at least five consecutive non-violative commercial shipments ^[21]. What it changes for a research buyer: nothing about legality, something about detention risk — a listing attaches to a firm and its products, so a consignment can be held on the strength of an earlier sample rather than anything in the box itself.

Canada has no statutory deemed-exclusion clock, but the detention power is explicit. Under section 101 of the Customs Act, goods that have been imported may be detained by an officer until the officer is satisfied they have been dealt with in accordance with that Act and any other Act of Parliament that prohibits, controls or regulates importation ^[16]. CBSA uses it to hold goods and refer them to Health Canada for an admissibility recommendation and disposition decision, with the costs of moving, destroying, disposing of or exporting inadmissible goods falling to the importer ^[3]. Health Canada's personal-use guidance states the same power from the other side: customs officers may detain any health product they suspect does not comply, and contact Health Canada to verify ^[17].

The personal-importation provisions do not reach research material. They describe a health product brought in for the importer's own use, or for a person or animal in their care, limited to a single course of treatment or a 90-day supply measured against the product's directions for use ^[17][3]. Material supplied for laboratory research carries no such directions, and neither document treats it as a personal import.

What the file has to hold afterwards

The import file outlives the shipment by years. US regulation requires records relating to an entry to be kept for five years from the date of entry, or from the date of the activity that generated the record ^[15]. Canada's period runs longer and has a location condition: records relating to the origin, purchase, importation, cost, value, payment and disposal of commercial goods must be kept for six years following the year of importation, normally at a place of business in Canada unless the agency authorises otherwise ^[14]. Keep the invoice, transport document, entry number, classification used, any ruling relied on and broker correspondence together, filed against the receiving record.

Where the public evidence is thin

Three honest limits. No published dataset gives detention or refusal rates for this commodity class at either border, so any quoted odds of examination are invented; what is public is the mechanism, not the frequency. Classification outcomes turn on composition, presentation and packing, which is why the reliable answer is a ruling on your facts rather than a code copied from a forum ^[13]. And the legal picture is moving: the US de minimis position changed twice within a year and remains in litigation ^[10][11], the 503A categories are under active committee review ^[19], and the Canadian position rests on a departmental advisory and an injunction against one named seller rather than on new legislation ^[1][2]. A document that calls the position simple and settled is telling you about its author, not about the border.